ArticleNeuropharmacology2021
Cannabinoid CB
Open access · greenAbstract read
In one paragraph
Article in Neuropharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Brain CB2 receptor: a new target in medication development for treating opioid use disorder in rodents.Molecular psychiatry · 2026Article
- The Effect of SERM/CBInternational journal of molecular sciences · 2026Article
- The relevance of cannabinoid receptor 2 in the central nervous system: an update over the last 3 years.Frontiers in behavioral neuroscience · 2026Review
- Neuronal versus Glial CB2 Receptors: Insights from a Novel CB2-KO-eGFP Reporter Mouse Line.Research square · 2025Article
- Anti-Inflammatory Effects of Cannabinoids in Therapy of Neurodegenerative Disorders and Inflammatory Diseases of the CNS.International journal of molecular sciences · 2025Review
- The effect of cannabinoid type Ⅱ receptor on the excitability of substantia nigra dopaminergic neurons.Frontiers in pharmacology · 2025Article
- Autophagy in alzheimer disease pathogenesis and its therapeutic values.Autophagy reports · 2025Review
- Enantiomeric Agonists of the Type 2 Cannabinoid Receptor Reduce Retinal Damage during Proliferative Vitreoretinopathy and Inhibit Hyperactive MicrogliaACS pharmacology & translational science · 2024Article
- Imaging and Genetic Tools for the Investigation of the Endocannabinoid System in the CNS.International journal of molecular sciences · 2023Review
- PPARα and PPARγ are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice.Molecular psychiatry · 2023Article
- PPARα and PPARγ are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice.Research square · 2023Article
- Update on the controversial identity of cells expressing cnr2 gene in the nervous system.CNS neuroscience & therapeutics · 2023Review
- Activation of oxytocin receptors in mouse GABAergic amacrine cells modulates retinal dopaminergic signaling.BMC biology · 2022Article
- A red nucleus-VTA glutamate pathway underlies exercise reward and the therapeutic effect of exercise on cocaine use.Science advances · 2022Article
- Hippocampal Cannabinoid 1 Receptors Are Modulated Following Cocaine Self-administration in Male Rats.Molecular neurobiology · 2022Article
- Cannabinoid 1/2 Receptor Activation Induces Strain-Dependent Behavioral and Neurochemical Changes in Genetic Absence Epilepsy Rats From Strasbourg and Non-epileptic Control Rats.Frontiers in cellular neuroscience · 2022Article
- Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits.Frontiers in neuroscience · 2022Review
- Receptor mechanisms underlying the CNS effects of cannabinoids: CBAdvances in pharmacology (San Diego, Calif.) · 2022Article
- Development of [International journal of molecular sciences · 2021Article
- β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors PossiblyFrontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Hai-Ying ZhangMolecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, 21224, USA.
Hui ShenSynaptic Plasticity Section, Cellular Neurobiology Research Branch, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, 21224, USA.
Ming GaoDepartment of Neurobiology, St. Joseph's Hospital and Medical Center, Barrow Neurological Institute, Phoenix, AZ, 85013, USA.
Zegang MaInstitute of Brain Science and Diseases, Qingdao University, Qingdao, Shandong, 266071, China.
Briana J HempelMolecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, 21224, USA.
Guo-Hua BiMolecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, 21224, USA.
Eliot L GardnerMolecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, 21224, USA.
Jie WuDepartment of Neurobiology, St. Joseph's Hospital and Medical Center, Barrow Neurological Institute, Phoenix, AZ, 85013, USA; Institute of Brain Science and Diseases, Qingdao University, Qingdao, Shandong, 266071, China. Electronic address: jiewubni@gmail.com.
Zheng-Xiong XiMolecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, 21224, USA. Electronic address: zxi@mail.nih.gov.
National Institute on Drug Abuse · USQingdao University · CNBarrow Neurological Institute · US
Funding
Basic brain mechanisms underlying drug addiction, craving, and relapseZIADA000478 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI GARDNER, ELIOT · 2009 to 2023
$7.9MCannabinoid CB1 and CB2 receptors and drug abuseZIGDA000633 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI XI, ZHENG-XIONG · 2020 to 2022
$3.6MCannabinoid CB1 and CB2 receptors and drug abuseZIADA000633 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI XI, ZHENG-XIONG · 2023 to 2025
$3.1MIntramural NIH HHS ZIA DA000633Intramural NIH HHS ZIG DA000633
Abstract
Cannabinoids produce a number of central nervous system effects via the CB
Indexed as
AnimalsCannabinoidsGene ExpressionGlutamic AcidMaleMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicMicroinjectionsMotor ActivityNeuronsReceptor, Cannabinoid, CB2Red Nucleus1,1-dimethylbutyl-1-deoxy-Delta(9)-THCCannabinoidsGlutamic AcidReceptor, Cannabinoid, CB2CannabinoidsCB(2) receptorGlutamate neuronsJWH133Motor behaviorRed nucleus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.